
Eli Lilly’s tug-of-war with the US Food and Drug Administration (FDA) over the treatment for adults with atopic eczema, Olumiant (baricitinib), is currently not looking to end favorably for the US-based pharmaceutical company.
In a news release, Eli Lilly warns its investors and the public that the company’s supplemental marketing application filed with the FDA could now end up in a rejection – a so-called ”complete response letter.”
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app